Adamas Pharmaceuticals, Inc.
(NASDAQ : ADMS)

( )
ADMS PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Are you a Dividend Trader
Learn how to make passive income from the best dividend stocks.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
AMRNAmarin Corporation Plc Sponsored ADR
-0.17%17.232.0%$167.83m
SAGESAGE Therapeutics, Inc.
2.44%139.799.5%$123.17m
PRGOPerrigo Co. Plc
2.30%45.906.8%$104.88m
JAZZJazz Pharmaceuticals Plc
1.32%129.072.2%$89.19m
GWPHGW Pharmaceuticals PLC Sponsored ADR
2.07%137.296.3%$77.26m
PTLAPortola Pharmaceuticals, Inc.
3.59%26.537.7%$57.20m
ICPTIntercept Pharmaceuticals, Inc.
-0.19%113.4518.6%$53.31m
AXSMAxsome Therapeutics, Inc.
-1.92%8.162.7%$45.95m
MNKMallinckrodt Plc
3.72%20.6421.1%$42.16m
CTLTCatalent Inc
1.12%35.612.4%$39.82m
ICLRICON Plc
-0.18%133.184.1%$39.17m
UTHRUnited Therapeutics Corporation
1.37%115.7514.4%$35.11m
ENDPEndo International Plc
-1.52%9.708.9%$34.69m
HZNPHorizon Pharma plc
-1.71%21.847.4%$25.74m
MDCOMedicines Company
0.25%20.0021.8%$25.48m

Company Profile

Adamas Pharmaceuticals, Inc. is a pharmaceutical company, which engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products includes ADS-5012, ADS-4101, and Namenda XR. The ADS-5102 is a treatment for levodopa-induced dyskinesia in patients with Parkinson's disease. The ADS-401 treats partial onset seizures in patients with epilepsy. The Namenda XR is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA.